Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,935,571 papers from all fields of science
Search
Sign In
Create Free Account
bleomycin/cytarabine/methotrexate/vincristine
Known as:
ARA-C/BLEO/MTX/VCR
, CytaBOM
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Bleomycin
Cytarabine
Methotrexate
Vincristine
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma
D. Longo
,
V. Devita
,
+8 authors
R. Young
2016
Corpus ID: 78855163
Table of the report entitled "Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive…
Expand
2006
2006
Randomized controlled study of proMACE-CytaBOM regimen in treatment of patients with relapsed or refractory intermediate and high grade non-Hodgkin’s lymphoma
G. Qi
2006
Corpus ID: 76447354
OBJECTIVE:To observe the clinical effect and toxicity of ProMACE-CytaBOM regimen in the treatment of patients with relapsed or…
Expand
2005
2005
Efficacy of Improved ProMACE/CytaBOM Regimen in Treatment of High Malignant and Middle Malignant Non-Hodgkin′s Lymphoma
Zheng Mei-fang
2005
Corpus ID: 76433280
Objective: To evaluate the efficacy of improved ProMACE/CytaBOM regimen in the treatment of high malignant and middle malignant…
Expand
2003
2003
Effect of ProMACE/CytaBOM regimen in treatment of refractory or relapse non-Hodgkin's lymphoma
Wang Shuhong
2003
Corpus ID: 76436726
Objective:To elucidate the effect of ProMACE/CytaBOM regimen in treatment of refractory and relapse non-Hodgkin's lymphoma…
Expand
Review
2002
Review
2002
Cyclin D 3 Is a Predictive and Prognostic Factor in Diffuse Large B-cell Lymphoma 1
M. Filipits
,
U. Jaeger
,
+5 authors
R. Pirker
2002
Corpus ID: 44212985
Cyclin D3 is an important regulator for transition from G1 to the S phase of the cell cycle. Cyclin D3 expression is associated…
Expand
2000
2000
ProMACE/CytaBOM Chemotherapy for Intermediate and High Grade Maliganant mon Hodgkin's Lymphoma
Ye Shu
2000
Corpus ID: 75392167
Objective:Evaluation of clinical response and toxic effects of ProMACE/CytaBOM in non Hodgkin's lymphoma.Methods:Among the 34…
Expand
1998
1998
A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.
T. Witzig
,
J. Camoriano
,
G. Schroeder
,
Paul J. Kurtin
,
T. Habermann
Leukemia and Lymphoma
1998
Corpus ID: 24631497
We hypothesized that the conventional ProMACE-CytaBOM regimen could be improved by administering all drugs on d1 with the S-phase…
Expand
1998
1998
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
G. Marotta
,
C. Bigazzi
,
M. Bocchia
,
F. Forconi
,
F. Lauria
Haematologica
1998
Corpus ID: 32719106
Long-lasting results achieved in 54 patients with aggressive non-Hodgkin lymphoma treated with Pro-MACE-CytaBOM regimen were…
Expand
1991
1991
Clinical effect of recombinant human granulocyte-stimulating factor in non-Hodgkin malignant lymphoma.
M. Okabe
,
K. Sakurada
,
Masanobu Kobayashi
,
I. Saiki
,
K. Matsuno
,
T. Minagawa
1991
Corpus ID: 74833190
To evaluate the clinical effect by administration of recombinant human granulocyte-stimulating factor (rhG-CS) post chemotherapy…
Expand